Evolution of the Average Target: Takeda Pharmaceutical Company Limited

Evolution of the Average Target - Takeda Pharmaceutical Company Limited

Evolution of the Target Price: Takeda Pharmaceutical Company Limited

Evolution of the Target Price - Takeda Pharmaceutical Company Limited

Changes in Analyst Recommendations: Takeda Pharmaceutical Company Limited

86285a5dcee.CsKwDOAjofRazq_1tJHTB2W-Vqfy6izDxYzNSY-KIcI.a6X8Q6ZAyYc3qduT4uahaS2HYO-_rk6FsOuhDcXQUphkidxbs037pQui3A~39a2e7d503aec7ab94f0ec64ac16a8cf
08-31 Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says MT
07-28 SBI Securities Starts Takeda Pharmaceutical at Neutral with 5,400 Yen Price Target MT
07-24 China Merchants Starts Takeda Pharmaceutical at Buy with 6,600 Yen Price Target MT
03-30 Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says MT
01-30 Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,700 Yen From 5,100 Yen, Keeps at Buy MT
11-11 Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study MT
25-09-26 Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says MT
25-08-20 Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says MT
25-05-09 Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,100 Yen From 5,500 Yen, Keeps at Buy MT
25-05-06 Jefferies Adjusts Takeda Pharmaceutical Company's Price Target to 5,500 Yen From 5,000 Yen, Keeps at Buy MT
24-08-12 Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,000 Yen From 4,800 Yen, Keeps at Buy MT
24-07-31 Jefferies Adjusts Takeda Pharmaceutical's Price Target to 4,800 Yen From 5,600 Yen, Keeps at Buy MT
24-02-13 Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,600 Yen From 5,200 Yen, Keeps at Buy MT
23-10-03 Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,200 Yen From 5,300 Yen, Keeps at Buy MT
23-09-22 Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,300 Yen From 5,100 Yen, Keeps at Buy MT
23-05-31 Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,100 Yen From 5,000 Yen, Keeps at Buy MT
23-05-16 TD Cowen Adjusts Price Target on Takeda Pharmaceutical to $20 From $30, Maintains Outperform Rating MT
23-04-04 TD Cowen Adjusts Price Target on Takeda Pharmaceutical to $30 From $24, Keeps Outperform Rating MT
23-03-16 BofA Securities Upgrades Takeda Pharmaceutical to Buy From Neutral, Price Target $20 MT
23-03-06 Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,000 Yen From 4,600 Yen, Keeps at Buy MT
22-08-01 Jefferies Downgrades Takeda Pharmaceutical to Hold From Buy MT
22-07-19 Cowen Upgrades Takeda Pharmaceutical to Outperform From Market Perform MT
21-10-07 Takeda Pharmaceutical : Morgan Stanley Downgrades Takeda Pharmaceutical to Equal-weight From Overweight MT
17-09-08 Bayer : Germany's Merck hires JP Morgan to sell consumer health RE

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+7.12%
+5.65%
+9.33%
-0.99%
-0.52%
+8.56%
-0.8%
+26.78%
-8.67%
+2.34%
Average +4.88%
Weighted average by Cap. +5.00%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
6,244.00JPY
Average target price
6,665.81JPY
Spread / Average Target
+6.76%
High Price Target
7,600.00JPY
Spread / Highest target
+21.72%
Low Price Target
5,800.00JPY
Spread / Lowest Target
-7.11%

Analyst Consensus Detail

Analyst consensus - Takeda Pharmaceutical Company Limited

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Takeda Pharmaceutical Company Limited
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Takeda Pharmaceutical Company Limited
  1. Stock Market
  2. Stocks
  3. 4502 Stock
  4. Consensus Takeda Pharmaceutical Company Limited